Citation: Dm. Friedland, CLINICAL PATHWAYS AND TREATMENT ALGORITHMS IN ONCOLOGY PATIENTS - NOTBAD BUT ARE THEY BENEFICIAL - COMMENT, Seminars in oncology, 25(3), 1998, pp. 19-19
Citation: Dm. Friedland, ADJUVANT CHEMOTHERAPY FOR HIGH-RISK BLADDER-CANCER - MUST WE WAIT FORTHE RESULTS OF LARGE MULTICENTER STUDIES, OR HAS THE QUESTION ALREADYBEEN ANSWERED - EDITORIAL COMMENT, Seminars in oncology, 24(6), 1997, pp. 23-24
Citation: Dm. Friedland, DOES HIGH-DOSE CHEMOTHERAPY HAVE A DEFINED ROLE IN THE TREATMENT OF SOLID TUMORS IN 1997 - EDITORIAL COMMENT, Seminars in oncology, 24(4), 1997, pp. 38-38
Authors:
STEVENSON J
GIANTONIO B
BOYD RL
BRUNER JA
FRIEDLAND DM
Citation: J. Stevenson et al., ADJUVANT CHEMOTHERAPY FOR BREAST-CANCER IN PREGNANCY - CAN RECOMMENDATIONS BE MADE WITH CONFIDENCE, Seminars in oncology, 24(2), 1997, pp. 25
Citation: Dm. Friedland, THERAPEUTIC OPTIONS FOR EARLY-STAGE HOPKINS DISEASE - AN EMBARRASSMENT OF RICHES OR A SNAKE IN THE GRASS - COMMENT, Seminars in oncology, 24(1), 1997, pp. 26-30
Citation: Dm. Friedland, CURRENT CLINICAL-PRACTICE - LOCALIZED PROSTATE-CANCER - ARE PROSTATECTOMY AND RADIATION-THERAPY EQUALLY EFFECTIVE OPTIONS - COMMENT, Seminars in oncology, 23(6), 1996, pp. 34-35
Citation: Dm. Friedland, INDIVIDUAL CHOICE AND MEDICAL LOGIC AT ODDS - WHO SHOULD DETERMINE THE LEVEL OF AGGRESSIVENESS IN CASES OF ADVANCED, INCURABLE CANCER - COMMENT, Seminars in oncology, 23(5), 1996, pp. 33-34
Citation: Dm. Friedland, WHAT SHOULD BE THE ROUTINE FOLLOW-UP AFTER DEFINITIVE THERAPY OF LOCALIZED LUNG-CANCER - COMMENT, Seminars in oncology, 23(4), 1996, pp. 27-28
Citation: Dm. Friedland, WHAT IS THE ROLE OF NEPHRECTOMY IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA - COMMENT, Seminars in oncology, 23(1), 1996, pp. 22-23
Citation: Sl. Aspinall et al., RECURRENT METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS OSTEOMYELITIS -COMBINATION ANTIBIOTIC-THERAPY WITH EVALUATION BY SERUM BACTERICIDAL TITERS, The Annals of pharmacotherapy, 29(7-8), 1995, pp. 694-697
Citation: Rl. Comis et Dm. Friedland, NEW CHEMOTHERAPY AGENTS IN THE TREATMENT OF ADVANCED NONSMALL CELL LUNG-CANCER - AN UPDATE INCLUDING DATA FROM THE 7TH WORLD CONFERENCE ON LUNG-CANCER, Lung cancer, 12, 1995, pp. 63-99
Citation: Dm. Friedland et Rl. Comis, PERIOPERATIVE THERAPY OF NON-SMALL-CELL LUNG-CANCER - A REVIEW OF ADJUVANT AND NEOADJUVANT APPROACHES, Seminars in oncology, 22(6), 1995, pp. 571-581
Authors:
ANDRUSS CM
DINELLA TJ
MACPHERSON DS
PIETROPAOLI AP
TSAO L
WACHMAN J
WHITTLE J
CAMERON ML
HINES JM
MCNEIL M
CONIGLIARO J
GOOD CB
LABKOFF SE
COHEN MG
DESWAL A
GULINSON MD
HANKIN LM
HEINLE MS
HIGHAM CJ
HOFFMANN EL
HUNN RH
HUNTER TM
KAM LW
LEON RJ
LILIE S
LIPINSKI JL
MARR LA
MCCULLUM KJ
MICHELSON GC
NACE DA
OROURKE DJ
OSBORN JL
PENDERGAST WJ
PROVENSANO MA
RAMSEY LC
REARDON LC
SANDBERG ML
SZAWALUK JJ
VANCLEEFF S
YOUNG MA
YEE EL
ZELDIN RK
BUSHMAN KE
RICHARDS SA
BALDERSTON V
CALDWELL KE
COLLINS ME
DIANESI EG
DALE CG
DIPPL JM
FINIKIOTIS MW
FINKEL RG
FRIEDLAND DM
GORBY RS
GUILINGER RA
HALLY RJ
HAMMERMAN SI
HARRIS JV
KEYES JV
LEUZZI RA
LUBICK CJ
MCGUINESS MA
NEEDLEMAN DC
PRITCHARD RJ
RODMAN MT
ROHN SG
SANTORA DM
SCHLOSS EJ
SELVAGGI TA
SHUSTER TD
STEIN AR
SWEET LJ
TEE ST
THOMAS A
HOGAN RC
KOSAR EM
MURTAUGH TI
Citation: Cm. Andruss et al., EFFECT OF DIGITAL RECTAL EXAMINATION ON SERUM PROSTATE-SPECIFIC ANTIGEN IN A PRIMARY-CARE SETTING, Archives of internal medicine, 155(4), 1995, pp. 389-392